Identification of a novel urokinase receptor splice variant and its prognostic relevance in breast cancer

Thrombosis and Haemostasis

Volumn 89, Issue 4, 2003, Pages 705-717

  Luther, Thomas ^a   Kotzsch, Matthias ^a   Meye, Axel ^a   Langerholc, Thomaz ^b   Füssel, Susanne ^a   Olbricht, Natalie ^b   Albrecht, Sybille ^a   Ockert, Detlev ^a   Muehlenweg, Bernd ^b   Friedrich, Katrin ^a   Grosser, Marianne ^a   Schmitt, Manfred ^b   Baretton, Gustavo ^a   Magdolen, Viktor ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer; LightCycler technology; mRNA; Splice variants; Urokinase receptor

Indexed keywords

MESSENGER RNA; UROKINASE RECEPTOR;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER TISSUE; CHINESE HAMSTER; CHO CELL; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; OVARY CELL; PLASMID; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; RNA SPLICING; RNA TRANSLATION; STATISTICAL ANALYSIS; WESTERN BLOTTING; WILD TYPE;

EID: 0037391933     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613577     Document Type: Article

References (51)

1. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
2. Koblinski JE, Ahram M, Sloane BF. Unraveling the role of proteases in cancer. Clin Chim Acta 2000; 291: 113-5.
3. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415-33.
4. Ellis V, Murphy G. Cellular strategies for proteolytic targeting during migration and invasion. FEBS Lett 2001; 506: 1-5.
5. Magdolen U, Krol J, Sato S, Mueller MM, Sperl S, Krüger A, Schmitt M, Magdolen V. Natural inhibitors of tumor-associated proteases. Radiol Oncol 2002; 36: 131-43.
6. Del Rosso M, Fibbi G, Pucci M, D'Alessio S, Del Rosso A, Magnelli L, Chiarugi V. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin Exp Metastasis 2002; 19: 193-207.
7. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int J Oncol 1998; 13: 893-906.
8. Muehlenweg B, Sperl S, Magdolen V, Schmitt M, Harbeck N. Interference with the urokinase plasminogen activator system: A promising therapy concept for solid tumours. Expert Opin Biol Ther 2001; 1: 683-91.
9. Sperl S, Mueller MM, Wilhelm OG, Schmitt M, Magdolen V, Moroder L. The uPA/uPAR system as a target for tumor therapy. Drug News Perspect 2001; 14: 401-11.
10. Preissner KT, Kanse SM, May AE. Urokinase receptor: A molecular organizer in cellular communication. Curr Opin Cell Biol 2000; 12: 621-8.
11. Chapman HA, and Wei Y. Protease crosstalk with integrins: The urokinase receptor paradigm. Thromb Haemost 2001; 86: 124-9.
12. 2-terminal amino acid sequence and glycosylation variants. J Biol Chem 1990; 265: 6453-60.
13. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Høyer-Hansen G, Smith K, Brünner N, Harris AL et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res 2002; 8: 1132-41.
14. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appella E, Blasi F. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9: 467-74.
15. Casey JR, Petranka JG, Kottra J, Fleenor DE, Rosse WF. The structure of the urokinase-type plasminogen activator receptor gene. Blood 1994; 84: 1151-6.
16. Pyke C, Eriksen J, Solberg H, Nielsen BS, Kristensen P, Lund LR, Danø K. An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator. FEBS Lett 1993; 326: 69-74.
17. Bianchi E, Cohen RL, Thor AT, Todd RF, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-6.
18. Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Müller M, Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Path 1997; 150: 1231-44.
19. Hildenbrand R, Leitz M, Magdolen V, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: Comparison with detection by non-isotopic in-situ hybridization. Histopathology 2000; 36: 499-504.
20. Magdolen V, Rettenberger P, Lopens A, Oi H, Lottspeich F, Kellermann J, Creutzburg S, Goretzki L, Weidle UH, Wilhelm O, Schmitt M, and Graeff H et al. Expression of the human urokinase-type plasminogen activator receptor in E. coli and Chinese hamster ovary cells. Purification of the recombinant proteins and generation of polyclonal antibodies in chicken. Electrophoresis 1995; 16: 813-6.
21. Schaefer BM, Stark HJ, Fusenig NE, Todd RF, and Kramer MD. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Exp Cell Res 1995; 220: 415-23.
22. Müller M. and Flössel C. Induktion und Bestimmung prokoagulatorischer Aktivität mononukleärer Zellen des menschlichen Blutes. Z Med Lab Diagn 1988; 29: 46-52.
23. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Precehtl A, and Graeff H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 1994; 54: 2527-30.
24. Luther T, Flössel C, Albrecht S, Kotzsch M, and Müller M. Tissue factor expression in normal and abnormal mammary gland. Nature Med 1996; 2: 491-2.
25. Lutz V, Reuning U, Krüger A, Luther T, Pildner Von Steinburg S, Graeff H, Schmitt M, Wilhelm OG, Magdolen V. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Biol Chem 2001; 382: 789-98.
26. Grosser M, Luther T, Müller J, Schuppler M, Bickhardt J, Matthiessen W, Müller M. Detection of M. tuberculosis DNA in sarcoidosis: Correlation with T-cell response. Lab Invest 1999; 79: 775-84.
27. Köhler T, Lerche D, Meye A, Weisbrich C, Wagner O. Automated analysis of nucleic acids by quantitative PCR using coated ready-to-use reaction tubes. J Lab Med 1999; 23: 408-14.
28. Kotzsch M, Luther T, Harbeck N, Ockert D, Lutz V, Noack F, Grossmann D, Albrecht S, Kramer MD, Lossnitzer A, Grosser M, Schmitt M, et al. and Magdolen V. New ELISA for quantification of human urokinase receptor (CD87) in cancer. Int J Oncol 2000; 17: 827-34.
29. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, and Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16: 7279-86.
30. Ploug M, Rahbek-Nielsen H, Nielsen PF, Roepstorff P, and Dano K. Glycosylation profile of a recombinant urokinase-type plasminogen activator receptor expressed in Chinese hamster ovary cells. J Biol Chem 1998; 273: 13933-43.
31. Behrendt N, and Stephens RW. The urokinase receptor. Fibrinol Proteol 1998; 12: 191-204.
32. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: Biology and regulation. Cell Mol Life Sci 1999; 56:104-32.
33. Ploug M, Gardsvoll H, Jorgensen TJ, Lonborg Hansen L, Dano K. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: A potential target for anti-invasive cancer therapy. Biochem Soc Trans 2002; 30:177-83.
34. Hoyer-Hansen G, Ploug M, Behrendt N, Ronne E, Dano K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997; 243: 21-6.
35. Ellis V, Scully MF, Kakkar VV. Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes. J Biol Chem. 1989; 264: 2185-8.
36. Ragno P, Montuori N, Covelli B, Høyer-Hansen G, and Rossi G. Differential expression of a truncated form of the urokinase-type plasminogen activator receptor in normal and tumor thyroid cells. Cancer Res 1998; 58: 1315-9.
37. Sidenius N, Sier CF, Blasi F. Shedding and cleavage of the urokinase receptor (uPAR): Identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Lett 2000; 475: 52-6.
38. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. J Biol Chem. 2002 Sep 23 [epub ahead of print; 277(49): 46932-9.]
39. Solberg H, Romer J, Brunner N, Holm A, Sidenius N, Dano K, Hoyer-Hansen G. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 1994; 58: 877-81.
40. Riittinen L, Limongi P, Crippa MP, Conese M, Hernandez-Marrero L, Fazioli F, Blasi F. Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand affinity. FEBS Lett 1996; 381: 1-6.
41. Foekens JA, Peters HA, Look MP, Portengen H, et al. Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-Van Gelder ME, Henzen-Logmans SC, Van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000; 60: 636-43.
42. Bouchet C, Hacene K, Martin PM, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F.: Dissemination risk index based on plasminogen activator system components in primary breast cancer. J Clin Oncol 1999; 17: 3048-57.
43. Mercatante DR, Sazani P, Kole R. Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases. Curr Cancer Drug Targets 2001; 1: 211-30.
44. Yousef GM, Diamandis EP. Human tissue kallikreins: A new enzymatic cascade pathway. Biol Chem 2002; 383: 1045-57.
45. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-102.
46. Caballero OL, De Souza SJ, Brentani RR, Simpson AJ. Alternative spliced transcripts as cancer markers. Dis Markers 2001; 17: 67-75.
47. Obermair A, Schmid BC, Packer LM, Leodolter S, Birner P, Ward BG, Crandon AJ, McGuckin MA, Zeillinger R. Expression of MUC1 splice variants in benign and malignant ovarian tumours. Int J Cancer 2002; 100: 166-71.
48. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002; 2: 9-15.
49. Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, Zeillinger R. Vascular endothelial growth factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res 2002; 8: 2253-9.
50. Okamoto I, Tsuiki H, Kenyon LC, Godwin AK, et al. Emlet DR, Holgado-Madruga M, Lanham IS, Joynes CJ, Vo KY, Guha A, Matsumoto M, Ushio Y, Saya H, Wong AJ. Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Path 2002; 160: 441-7.
51. Magklara A, Scorilas A, Katsaros D, et al. Massobrio M, Yousef GM, Fracchioli S, Danese S, Diamandis EP. The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001; 7: 806-11.